← Back
Biovie
BIVI · listed on Nasdaq · worth $12.68 million
$1.42
−4.20% on Nov 2
Four insider buys in the last year, $49.1K in all. None in the last two weeks.
Different buyers at once4 insiders bought, and 3 big investors reported new stakes, within 4 weeks · Sep 3
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
7.5M shares
86% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought Biovie stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
President & CEO
Cuong V. Do
Bought $31.6K on Aug 27 — 15,210 shares at $2.08, 94% of what they now own.
No earlier purchases to measure
Chief Medical Officer
Joseph M. Palumbo
Bought $10.5K on Aug 28 — 4,843 shares at $2.16, 80% of what they now own.
First purchase we have on file
Chief Financial Officer
Joanne Wendy Kim
Bought $5.5K on Aug 28 — 2,500 shares at $2.18, 73% of what they now own.
First purchase we have on file
Big investors
People and funds that reported owning 5% or more of Biovie, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.Jane Street Group5.2%Sep 3
Filed by someone who owns 5% or more and does not plan to influence the company.Alta Partners LLC8.4%Aug 19
Filed by someone who owns 5% or more and does not plan to influence the company. · updateMorgan Stanley11.9%Aug 7Reported stake, oldest first: 8.0% (Aug 7) → 11.9% (Aug 7)Crossed 10%
Filed by someone who owns 5% or more and does not plan to influence the company.Morgan Stanley8.0%Aug 7
Each history starts at the oldest report we hold.
All reports
Every insider trade and SEC report we hold for Biovie.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Analysts, earnings and news
Analysts' price target
$5.26 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
0 of 1 quarters above
Q3 '25−$0.98 a share−$0.19